Physician profile
Thomas A Blessey
NPI 1326195694
$8,822.90
in general payments reported to CMS, 2019-2025
40 companies · $922 in 2025
The $922 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $875 · 2020: $1,217 · 2021: $2,052 · 2022: $1,360 · 2023: $1,320 · 2024: $1,076 · 2025: $922.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,318.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,317.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,916.05 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $953.18 | 2020-2025 | Ubrelvy, Qulipta |
| Astrazeneca Pharmaceuticals LP | $820.34 | 2019-2025 | Farxiga, Lokelma, Airsupra |
| Abbott Laboratories | $542.31 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2, Tacticath Ablation Catheter, Sensor Enabled |
| Janssen Pharmaceuticals, INC | $539.33 | 2020-2022 | |
| Lilly USA, LLC | $490.55 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amarin Pharma, INC. | $333.60 | 2020-2023 | |
| Pfizer INC. | $309.10 | 2019-2025 | |
| Amgen INC. | $286.18 | 2019-2025 | Otezla, Repatha, Evenity |
| Merck Sharp & Dohme LLC | $266.70 | 2019-2023 | Verquvo, Januvia, Belsomra |
| Xeris Pharmaceuticals, INC. | $264.18 | 2021-2025 | Gvoke Hypopen |
| Corcept Therapeutics | $179.36 | 2022-2024 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $174.31 | 2020-2024 | Jardiance, Tradjenta |
| Novartis Pharmaceuticals Corporation | $166.17 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $140.34 | 2021-2024 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Blessey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.